About This Reference Desk

What Peptides in Texas is

Peptides in Texas is an independent editorial reference desk covering the published research on two peptides studied for immune resilience and host-defense: Thymosin Alpha-1 and KPV. "Texas" is a brand name — there is no physical office, no local business, no appointment line, and nothing for sale here. The name is not a claim about geographic location or the availability of services.

The site exists to make a technically demanding, uneven, and frequently overstated literature legible to a general reader. For each compound it reports what was studied, in which species (and how many subjects), with what result, as cited from the peer-reviewed record. Where the evidence is strong, we say so. Where it is thin, preclinical, or outright null — as in the 2025 phase-3 TESTS trial of thymalfasin in sepsis — we say that too, without softening.

The organizing idea is that immune modulation is a two-directional problem: restoring competence in a suppressed system and calming excess in a hyperactivated one. Thymosin Alpha-1 is studied for the first; KPV is studied for the second. Reading them together gives a fuller picture of the field than either provides alone.

Editorial method

Each compound page is built from peer-reviewed sources: clinical trial reports, mechanistic studies in human cell lines and animal models, pharmacokinetic analyses, and systematic reviews. Sources are cited by number and linked to a single shared references list that aggregates every source in one place.

The desk applies a consistent critical lens across all compounds:

• Species and study design are always stated. A finding in DSS-induced colitis in C57BL/6 mice is reported as such, not paraphrased into a human claim.
• Null results are reported as fully as positive results. The 2025 TESTS phase-3 trial of thymalfasin in sepsis — which found no significant mortality benefit — is described in the same detail as earlier positive signals.
• Regulatory status is stated plainly. Whether a compound is FDA-approved, internationally approved under a different name, or research-use only is stated at the compound level, not tucked into a disclaimer.
• No doses, no protocols, no recommendations. When a dose appears in a study description, it is reported as a study parameter — for example, "subcutaneous thymalfasin at [dose range] in a randomized controlled trial of 361 adults" — never as advice for any person.

The desk does not accept advertising. It has no commercial relationship with any supplier of these compounds.

Independence and disclaimer

Peptides in Texas is an independent editorial project. It does not sell products, compounds, or services of any kind. It does not provide medical, clinical, or pharmaceutical advice. Nothing on this site should be read as a treatment recommendation or as guidance on human use of any research chemical.

The compounds covered here are research peptides. They are studied in laboratories and in clinical trials by credentialed researchers in institutional settings with regulatory oversight. This desk summarizes that published science. It does not replicate those conditions, and it is not a substitute for consultation with a qualified medical professional.